% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • ahhaha2 ahhaha2 Nov 3, 2012 12:11 AM Flag

    The CC, Q&A, BMO Cap

    Jim Birchenough - BMO Capital Markets U.S.

    with Kyprolis. What kind of discontinuation rates are you seeing in patients treated?

    second question, just a reminder on the ASPIRE study. Is the Revlimid in the control arm being dosed to progression, i.e., maintenance? Or is it dosed for just an induction period?


    It's probably too early to talk about discontinuation for Kyprolis. Helen's nodding her head, yes. So I think that's the answer on that one. And then have -- Barb, comment a little bit, if you can, about the dosing for Revlimid and ASPIRE.

    Barbara Klencke

    I'll quickly say that we are dosing the Revlimid to progression.